PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-9.09%
Both companies show declining cash positions (-9.09% vs AXSM's -4.70%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-9.09%
Cash + STI yoy ≥ 1.5x AXSM's -4.70%. David Dodd might see it as a strategic cash buffer advantage. Evaluate deployment plans.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-38.56%
Other current assets growth < half of AXSM's 15.02%. David Dodd sees a leaner approach to short-term items.
-10.41%
≥ 1.5x AXSM's -1.52%. David Dodd might see a short-term liquidity advantage or potential underutilized capital.
-5.27%
≥ 1.5x AXSM's -1.34%. David Dodd sees more aggressive capex. Confirm it's not overspending.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.98%
Higher Long-Term Investments Growth compared to AXSM's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.72%
≥ 1.5x AXSM's -3.11%. David Dodd sees significantly higher long-term asset buildup. Confirm synergy with strategy.
No Data
No Data available this quarter, please select a different quarter.
-10.20%
≥ 1.5x AXSM's -1.76%. David Dodd notes a larger balance sheet expansion. Confirm it's not overleveraged.
-5.64%
Less than half of AXSM's -32.26%. David Dodd sees a more disciplined AP approach or lower volume.
1.56%
Less than half of AXSM's 25.14%. David Dodd sees much smaller short-term leverage burden vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.56%
Less than half of AXSM's 30.06%. David Dodd sees fewer expansions in other current obligations.
-5.23%
Above 1.5x AXSM's -0.27%. Michael Burry sees a red flag for liquidity risk vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.36%
50-75% of AXSM's -0.54%. Bruce Berkowitz notes a smaller yoy liability buildup than competitor.
No Data
No Data available this quarter, please select a different quarter.
-1.33%
Above 1.5x AXSM's -0.45%. Michael Burry sees a potential leverage warning sign.
No Data
No Data available this quarter, please select a different quarter.
-4.21%
Below half AXSM's -9.22%. Michael Burry suspects major net losses or high dividends vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-17.89%
≥ 1.5x AXSM's -3.33%. David Dodd sees stronger capital base growth than competitor.
-10.20%
≥ 1.5x AXSM's -1.76%. David Dodd sees faster overall balance sheet growth than competitor.
0.98%
Higher Total Investments Growth compared to AXSM's zero value, indicating better performance.
-5.39%
Less than half of AXSM's 0.47%. David Dodd sees less overall debt expansion vs. competitor.
9.19%
Similar yoy changes to AXSM's 8.48%. Walter Schloss sees parallel net leverage strategies.